Cancer immunotherapy relies on T cells recognizing and attacking tumor cells, but predicting which cancer peptides will trigger this response has been challenging. This perspective reviews how advances in sequencing technologies and computational methods are improving our ability to predict T cell epitope recognition. The authors highlight progress in understanding TCR-epitope interactions and how these insights could enhance therapeutic strategies by better leveraging patient TCR repertoires for personalized cancer treatment.
